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CTLHuman cytomegalovirus (HCMV) encodes four glycoproteins, termed gpUS2, gpUS3, gpUS6 and gpUS11 that
interfere with MHC class I biosynthesis and antigen presentation. Despite gpUS2–11 expression, however,
HCMV infection is efﬁciently controlled by cytolytic CD8 T lymphocytes (CTL). To address the role of gpUS2
and gpUS11 in antigen presentation during viral infection, HCMV mutants were generated that expressed
either gpUS2 or gpUS11 alone without coexpression of the three other proteins. Fibroblasts infected with
these viruses showed reduced HLA-A2 and HLA-B7 surface expression. Surprisingly, however, CTL directed
against the tegument protein pp65 and the regulatory IE1 protein still recognized and lysed mutant virus
infected ﬁbroblasts. Yet, suppression of IE1 derived peptide presentation by gpUS2 or gpUS11 was far more
pronounced. The results show that gpUS2 and gpUS11 alone only incompletely protect HCMV infected
ﬁbroblasts from CTL recognition and underline the importance of studying infected cells to elucidate HCMV
immune evasion.© 2009 Elsevier Inc. All rights reserved.IntroductionInfection with the human cytomegalovirus (HCMV) may lead to
severe and life threatening disease conditions in individuals with
impaired or immature immune defense functions. In contrast, HCMV
infection is readily controlled by the immune system in healthy indi-
viduals, rarely leading to overt clinical manifestations (Mocarski et al.,
2007). Both in murine models and in clinical studies, it could be shown
that cytolytic CD8 T lymphocytes (CTL) aremajor immunologic effectors
that mediate protection against CMV disease (Reddehase et al., 1987;
Walter et al., 1995). However, despite the obvious efﬁciency of CMV
speciﬁc CTL, these cells cannot prevent the establishment of viral
latency. Latent infection may be interrupted by episodes of reactivation,
which again are controlled by CTL (Simon et al., 2006). CMV infections
are thus characterized by an intricate balance between an efﬁcient
immune surveillance by the host and CMV speciﬁc mechanisms that
help the virus to evade complete immune control and eradication.
HCMV has evolved multiple strategies to interfere with both the
innate and the adaptive immune response of its host. These topics
have been covered by recent reviews (Braud et al., 2002; Lilley and
Ploegh, 2005; Mocarski, 2004; Reddehase, 2002; Tortorella et al.,
2000). Major interest of research has focused on the impairment of
recognition of infected cells by CTL. Early work described down-
modulation of major histocompatibility complex class I (MHC class I).
ll rights reserved.molecules on the surface of HCMV infected human ﬁbroblasts (HF)
(Barnes and Grundy, 1992), leading to an impairment of CTL mediated
cytolysis (Khan et al., 2005; Manley et al., 2004). Deletion mutagen-
esis identiﬁed a region on the 230 kbp DNA genome of HCMV,
encompassing the putative open reading frames US2 to US11, which
genetically deﬁned theMHC class I downmodulation phenotype of the
virus (Jones et al., 1995). In this latter work, Jones et al. speciﬁed the
US11 gene as one, but not the sole determinant that affected MHC
class I biogenesis in HCMV infected cells. Later investigations addi-
tionally deﬁned the proteins encoded by US2, US3 and US6 to inde-
pendently mediate MHC class I downregulation in cells expressing the
individual genes (Ahn et al., 1996; Ahn et al., 1997; Jones et al., 1996;
Wiertz et al., 1996b). The four gene products gpUS2, gpUS3, gpUS6
and gpUS11 (herein concisely termed gpUS2–11) were thus deﬁned as
immune evasins.
The gpUS2 and gpUS3 have also been found to interfere with MHC
class II antigen presentation (Hegde et al., 2002; Tomazin et al., 1999),
and gpUS2 was reported to cause degradation of the nonclassical class
I MHC complex molecule HFE (Ben-Arieh et al., 2001). Furthermore,
variations in the efﬁciency of MHC class I downmodulation by gpUS2–
11 after infection of different cell types have been described (Rehm
et al., 2002; Schust et al., 1998). In particular, the efﬁciency of gpUS2–
11 in downmodulating MHC class I and class II in professional antigen
presenting cells may be limited, which may explain the efﬁcient
priming of an antiviral immune response despite immune evasion.
Recent evidence frommurine CMV (MCMV) infection even point to an
enhancing effect of the homologous MCMV proteins on priming
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during the acute or reactivated infection, HF support HCMV replica-
tion (Sinzger et al., 1995). These cells are thus a major target of anti-
viral CD8 Tcells in order to limit infection. Consequently, investigating
the effect of gpUS2–11 after infection of HF provides important infor-
mation about the role of evasion for the control of infection.
MHC class I molecules are heterotrimeric complexes consisting of a
variant heavy chain, the invariant β2-microglobulin chain and an
antigenic peptide (Townsend et al., 1989). These peptides are derived
from cellular or viral proteins, which are degraded in the cytosol by
proteasomes and are transported by the transporter associated with
antigen presentation (TAP) into the lumen of the ER (Yewdell and
Bennink, 2001). Peptides with appropriate lengths and binding motifs
are then loaded onto particular MHC class I molecules, a process
mediated by ER-resident chaperons (Bouvier, 2003). Assembled MHC
class I complexes are subsequently transported to the cell surface,
where they engage with antigen speciﬁc T cell receptors on CTL,
leading to the activation of the effector functions of these lymphocytes
(Heemels and Ploegh, 1995).
The viral glycoproteins gpUS2, gpUS3, gpUS6 and gpUS11 have
been shown to interfere at various stages with this process of MHC
class I biosynthesis (reviewed in Lilley and Ploegh, 2005; Loenen et al.,
2001; Powers et al., 2008; Reddehase, 2002). The early proteins gpUS2
and gpUS11 both mediate the dislocation of MHC class I heavy chains
(HC) to the cytosol, where the latter proteins are degraded by the
proteasome (Wiertz et al., 1996b,1996a). However, gpUS2 and gpUS11
differ in several ways with respect to their interactionwith HC and the
mechanisms, by which they induce cytoplasmic translocation of MHC
class I molecules (reviewed in Lilley and Ploegh, 2005; Powers et al.,
2008). The gpUS2 contacts the HC between the peptide binding
groove and the α3-domain (Gewurz et al., 2001a). The interaction
domain is intrinsic for only a portion of the human HLA allomorphs,
implying allele speciﬁc degradation mediated by gpUS2 (Barel et al.,
2003b; Gewurz et al., 2001b). In contrast, gpUS11 appears to bind to
the α1–2-domains of HC, which renders the viral protein less speciﬁc
in its capabilities to induce degradation of different HLA allomorphs
(Barel et al., 2003a). Furthermore, gpUS2- and gpUS11-mediated trans-
location of HC requires different cellular factors (Lilley and Ploegh,
2004; Loureiro et al., 2006). Finally, gpUS2 only acts on HC that have
been correctly folded, whereas gpUS11 degrades free HC or HC-β2m
complexes (Gewurz et al., 2001a; Lilley and Ploegh, 2005). All of this
together indicate that gpUS2 and gpUS11 have evolved to target diffe-
rent cellular pathways in order to achieve the same goal, namely trans-
location and degradation of MHC class I molecules during HCMV
infection.
The gpUS2 and gpUS11 have been instrumental for our under-
standing of the mechanisms of ER protein quality control and protein
dislocation from the ER to the cytosol. On the other hand, a lot has
been learned about the molecular interaction of the two proteins with
the MHC class I pathway (reviewed in detail in Lilley and Ploegh,
2005). Sole expression of gpUS2 or gpUS11 interferes withMHC class I
biosynthesis in HCMV infected ﬁbroblasts (Jones et al.,1995; Jones and
Sun, 1997). In addition, infection with HCMV mutants that expressed
either gpUS2 or gpUS11 mediated degradation of HC that had been
accumulated in the ER of gpUS3 expressing U373-MG cells (Jones and
Sun, 1997). A cooperative effect of gpUS2 and gpUS3 was recently
shown by coexpression of the two proteins in U373-MG cells (Noriega
and Tortorella, 2009). Infection with gpUS2/US3pos or gpUS6/
US11pos HCMV mutants resulted in MHC class I downregulation at
24 h p.i. and moderate to intermediate reduction of infected-cell
cytolysis by HCMV speciﬁc CTL, compared to a US2–11 deletion
mutant (Khan et al., 2005). However, one major unresolved issue is
the role that gpUS2 and gpUS11 individually play to protect cells
against recognition and cytolysis by CTL in the course of viral infection.
To address this question, mutants of HCMV were generated in
which the open reading frames US3, US6 and US11 or US2, US3 andUS6 were deleted sequentially from the viral genome. The resulting
viral mutants expressed either gUS2 or gpUS11, but none of the three
other immune evasins, respectively. All mutants retained the
sequences encoding the open reading frames (orfs) US4–5 and US7–
10 to be able to exclude any inﬂuences of these genes on MHC I
presentation. Permissive human foreskin ﬁbroblasts (HFF) infected
with these mutants showed downregulation of HLA-A2 and HLA-B7.
Yet, CTL directed against the immunodominant viral proteins pp65
and IE1 were still stimulated by HF infected with the mutant viruses,
although to variable extent. Our results show that the impact of gpUS2
and gpUS11 expression in the absence of other MHC class I modulators
of HCMV is remarkably limited, indicating that suppression of MHC
class I antigen presentation by HCMV requires the concerted activity
of all immune evasins.
Results
Generation of HCMV immune evasion mutants
The objectives of this work were to investigate the roles of gpUS2
and gpUS11, individually, in MHC class I downmodulation and
protection against CTL recognition of HCMV infected cells. To be
able to address this issue, viral mutants were generated in which the
three other members of the US2–11 evasion genes of HCMV were
removed from the viral genome. Furthermore, carewas taken to retain
the coding sequences for the US4–5 and US7–10 gene regions in the
resulting viral recombinants. This appeared to be important as
preliminary information from other laboratories on possible interac-
tions of proteins encoded in the US7–10 region with MHC class I was
available (Furman et al., 2002; Tirabassi and Ploegh, 2002). Mutagen-
esis of the viral genome in Escherichia coli was employed using the
bacterial artiﬁcial chromosome (BAC) clone pAD/Cre (Brune et al.,
2006; Lee et al., 2001; Yu et al., 2002). The Ad169 derived pAD/Cre
contained the BAC vector and an expression cassette for the Cre
recombinase, ﬂanked by LoxP sites and inserted between the viral
genes US28 and US29. Transfection of pAD/Cre derived clones into
HFF leads to the site-speciﬁc excision of the BAC vector and the Cre
gene in the course of viral reconstitution (Yu et al., 2002).
The orfs US3, US6 and US11 were deleted in sequential steps from
pAD/Cre, using λ-Red recombination mediated genetic engineering
(Recombineering; Lee et al., 2001; Mersseman et al., 2008b). The ﬁnal
BAC pKB13 consequently lacked the complete orfs (from start to stop
codons) of US3, US6 and US11 (Fig. 1) and had a US2pos/US3neg/
US6neg/US11neg genotype. An analogous BAC (pKB9) which only had
the US11 orf retained was constructed using the same strategy (Fig. 1).
This BAC was thus US2neg/US3neg/US6neg/US11pos. An additional
mutant with precise deletion of all four orfs was generated for control
(pKB6). All three BACs, pKB13, pKB9 and pKB6 retained the US4–5 and
US7–10 gene regions.
The genomic structure of the recombinant BACs was analyzed by
restriction endonuclease digestion (BamHI) and agarose gel electro-
phoresis. The desired modiﬁcations in the genomic region of interest
could be veriﬁed by shifts in the restriction pattern of the respective
BAC clones (Fig. 1B). In addition, Southern blot analysis with US2, US3,
US6 and US11 speciﬁc probes was used to verify the proposed
genotype (Fig.1C). DNA of pAD/Cre showed hybridizationwith probes
speciﬁc for each of the four US genes. Hybridization with the US2
speciﬁc probe was only detectable in pKB13 DNA and US11 speciﬁc
hybridization was only found in pKB9 DNA. No hybridization with the
US2 and US11 probes was found in pKB6 DNA and hybridization with
either a US3 or a US6 speciﬁc probe was undetectable in the DNA from
any of the three mutants. In addition, the deletion of the respective
genes was veriﬁed by PCR analysis and nucleotide sequencing of the
BAC clones (data not shown). These analyses unequivocally proved
that HCMV BACs that retained either US2 only, US11 only or none of
the US2–11 evasion genes had been generated. The BAC DNAs were
Fig. 1. Construction and veriﬁcation of recombinant BACs. (A) Schematic representation
of recombinant HCMV BACs. The genome of the Ad169 strain of HCMVwith the location
of the US2–11 gene region is shown on top. This region of interest is blown up in the
maps below (not drawn to scale). The location of the orfs encoding US2, 3, 6 and 11 are
shown by dark grey boxes. Restriction sites for BamHI are indicated on top of each
construct, the sizes of the fragments after digestion with BamHI are shown below.
Further to that, the KanR and AmpR genes and the FRT sites used for constructing the
BACs are also depicted. (B) Agarose gel electrophoresis of DNA of the different BACs,
cleaved with BamHI. The expected alterations in electrophoretic mobility of the 10.5 kb
fragment of pAD/Cre are indicated by white circles, alterations of the 7 kb fragment are
indicated by white dots. (C) Southern blot analysis of DNA from the different BACs,
digested with BamHI. The probes used for hybridization are indicated on the left side of
each blot.
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reconstituted (Borst et al., 1999).
Veriﬁcation of the kinetics of replication and US2 and US11 gene
expression of the viral mutants
One major focus of this study was to investigate the impact of
gpUS2 and gpUS11 on antigen presentation at different time points
after HCMV infection. The members of the US2–11 genes had been
shown to be non-essential for replication in HFF (Dunn et al., 2003).
However, a mutant lacking the genes US1–US15 had been reported to
display a temperature-sensitive phenotype, indicating that importantfunctions for viral replication were encoded in this region (Kollert-
Jöns et al., 1991). It thus was mandatory to show that the mutant
viruses generated here did not differ in their capacity to replicate in
permissive cells and that the kinetics of expression of gpUS2 and
gpUS11, respectively was comparable to the wild type (wt) situation.
In a ﬁrst step, single cycle growth kinetics were analyzed to test the
capacity of the different viral strains to release infectious viral
progeny. HFF were infected with the various mutants at an moi of 5.
Cell culture supernatants were analyzed for infectivity at different
time points p.i. by quantifying IE1 positive cells 48 h after infection
with the different supernatants (Fig. 2A). The release of IE1 forming
units was comparable betweenwt virus RV-BADwt and the 3 different
viral strains, showing that there was no impairment of any of the
mutant strains to pass through the viral replication cycle.
To study viral replication in more detail, in a second step initiation
and course of viral DNA replication was analyzed using TaqMan PCR
on DNA, isolated from HFF at different time points after infectionwith
the various mutants (Fig. 2B). Levels of viral DNA of the mutants at
different times p.i. were comparable to the DNA-levels of the wt virus
RV-BADwt showing that the mutants were not impaired in their
ﬁtness to replicate in permissive cells. Finally, the release of DNA-
containing particles from HFF was measured using TaqMan PCR
quantiﬁcation of viral DNA, isolated from infected cell culture
supernatant at different times after infection (Fig. 2C). The amount
of DNA detectable at each time point tested was indistinguishable
between each of the individual mutants and RV-BADwt. This indicated
that the mutants were unimpaired in their synthesis and release of
viral progeny.
To verify that the expression kinetics of US2 and US11 in cells
infected with the mutants was comparable to that in wt HCMV
infected cells, Northern blot analyses were performed. RNAs of 0.9 kb
and 1.1 kb, respectively could be detected in total cell RNA pre-
parations of RV-BADwt infected cells, using US2 or US11 speciﬁc
probes (Fig. 3). The signals could ﬁrst be detected at 6 h p.i. for both
US2 and US11. Signal intensity reached a maximum at about 12 h p.i.
and declined thereafter. Only vague signals were detectable at 72 h p.
i.. Sizes of the fragments and kinetics of expression complied with
previously published results, classifying US2 and US11 as being early–
late genes (Chau et al., 1999; Jones and Muzithras, 1991; Jones and
Sun, 1997).
Probing RNA from RV-KB13 infected cells with the US2 speciﬁc
probe showed hybridizationwith the 0.9 kb RNA, as expected. Kinetics
of expression of the US2 speciﬁc transcript was indistinguishable in
RNA preparations from cells infected with RV-KB13 or the parental
strain RV-BADwt (Fig. 3, upper panel). Using the US11 speciﬁc probe
on RNA obtained from RV-KB9 infected cells showed the expected
signal of 1.1 kb, with the same expression kinetics as detected in RV-
BADwt infected cells (Fig. 3, lower panel). These blots conﬁrmed that
the genetic manipulations applied to delete the three other evasin
genes did not alter the expression from the remaining genes US2
or US11. Finally, both the US2 and the US11 speciﬁc probes were
hybridized to RNA obtained from RV-KB6 infected cells. As expected,
no US2 or US11 RNA expression could be detected in RV-KB6 infected
cells. Taken together, these results showed that the recombinant
viruses displayed no apparent growth deﬁciency and that expression
kinetics of the remaining evasin genes were conserved in themutants.
gpUS2 and gpUS11 independently reduce MHC class I expression on
infected cells
Early studies had shown that HF display a signiﬁcant reduction of
MHC class I surface expression during HCMV infection, as measured
by ﬂow cytometry (Barnes and Grundy, 1992). Deletion of US2–11 in
recombinant viruses resulted in abrogation of this effect (Jones et al.,
1995) and expression of only US2/US3 or US6/US11 by viral mutants
showed intermediate downregulation of MHC I compared to that seen
Fig. 2. Growth kinetics of the recombinant viral strains in comparison to the wild type strain RV-BADwt. HFF were infected with an moi of 5 (A) or with infectious culture
supernatants that were normalized for an equivalent uptake of 4 viral genomes per cell (B, C). (A) Single cycle growth analysis of different viral mutants. At the indicated time points
p.i., cell culture supernatants were harvested for quantiﬁcation of viral titers by staining of infected ﬁbroblasts for expression of the HCMV IE1 protein. Means and standard deviations
for each data point were derived from 8 samples. (B) Kinetics of genome replication of the different viral mutants. At the indicated time points p.i., DNA was isolated from infected
cells and the amount of viral DNA was measured using quantitative TaqMan DNA PCR analysis. (C) Kinetics of infectious, DNA-containing particle release from infected cells. At the
indicated time points p.i., cell culture supernatants were collected. Viral DNA in each specimen was analyzed by quantitative TaqMan DNA PCR analysis. (B, C) Means of triplicate
samples of one out of two independent experiments are shown in each case. SN, supernatant.
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gpUS11 alone, however, on MHC class I surface expression of infected
cells at different times p.i. remained unclear from these analyses. The
availability of mutants expressing only gpUS2 or gpUS11 allowed us to
ask the question about the contribution of each of the two evasins. HFF
were infected for 1, 2, 3 and 4 days with the different viruses. Cells
were subsequently analyzed by Fluorescence Activated Cell Sorting
(FACS; Fig. 4A). As expected, cells infected with the gpUS2–11pos wt
virus RV-BADwt showed a marked reduction of MHC class I surface
expression, as measured using the HLA-ABC speciﬁc antibody W6/32.
This was especially prominent at 2, 3 and 4 days p.i.. Infectionwith RV-
KB13, expressing only gpUS2 of the four evasins gpUS2–11 (herein
concisely termed US2pos virus) or RV-KB9, expressing only US11
(herein concisely termed US11pos virus), however, led to an only
moderate reduction of HLA-ABC at different times p.i., as compared
with uninfected cells. Surprisingly, this downregulation could not be
enhanced by coinfection with RV-KB13 and RV-KB9.
For FACS analyses of MHC class I expression on the surface of
infected cells, expression on uninfected cells is frequently used as a
reference. It has been shown, however, that cells that are infected with
a US2–11neg virus may even upregulate their MHC class I surface
expression (Falk et al., 2002). We have also seen this in our
experiments, using the US2–11neg virus RV-KB6 (Fig. 4A). It was
thus conceivable that slight reductions of MHC class I mediated by
gpUS2 or gpUS11 expression in infected cells were masked by this
upregulation. Consequently we decided to use, for further experi-
ments, RV-KB6 infected cells instead of uninfected cells as a reference
(100%) for the expression of MHC class I on RV-BADwt, RV-KB13 or
RV-KB9 infected cells. The results of three independent experimentsare shown in Fig. 4B. Indeed a clear reduction of HLA-ABC on both RV-
KB13 (US2pos) and RV-KB9 (US11pos) infected HFF became apparent,
using this approach. This reduction was more pronounced in the later
stages of infection. Neither gpUS2 nor gpUS11 expression alone,
however, was sufﬁcient to reduce MHC class I to levels, seen in wt
virus (RV-BADwt) infected cells. These experiments showed that MHC
class I surface expression on infected cells is impaired by gpUS2 or
gpUS11 alone, but that this downregulation does not reach wt levels.
Both HLA-A2 and HLA-B7 are downregulated on gpUS2pos and
gpUS11pos infected cells
gpUS2 and gpUS11 interact with different portions of MHC class I
molecules in the ER (Barel et al., 2003a, 2003b; Gewurz et al., 2001a).
The gpUS11 binding domain appears to be conserved between
different HLA molecules. This was used to explain that gpUS11 could
attack different HLA-A and HLA-B locus products (Barel et al., 2003a,
2003b; Lilley and Ploegh, 2005). In contrast, the residues of the
binding site for gpUS2 on HLA-A2 are less well conserved in other HC
(Barel et al., 2006; Gewurz et al., 2001a). This served as background
for the ﬁnding that gpUS2 is not sufﬁcient to attack certain HLA-B and
HLA-C products, in particular HLA-B7 (Barel et al., 2003b, 2006; Llano
et al., 2003). The latter investigations, however, were all carried out
after transfection or retroviral transduction. To test the impact of
gpUS2 and gpUS11 on HLA-A2 and HLA-B7 surface expression on
infected cells, HFF were infected with either RV-KB13, RV-KB9 or
coinfected with both viruses (Fig. 5). Surface expression of HLA-A2 or
HLA-B7 was measured by FACS at different time points after infection.
Again, HLA-A2 or HLA-B7 expression on cells infected with the US2–
Fig. 3. Analysis of US2 and US11 RNA expression kinetics of parental and recombinant
viral HCMV strains in the course of infection. HFF were infected with viral inocula that
were normalized for an equivalent uptake of 125 viral genomes per cell. At the indicated
time points p.i., total cellular RNA was isolated and subsequently separated by
denaturing agarose gel electrophoresis (8 μg RNA per lane). After blotting, RNAs were
hybridized to US2 (upper panel) and US11 speciﬁc (lower panel) probes. Positions of
cellular 18S and 28S rRNAs are indicated on the right side of agarose gels. The rRNAs
were taken as loading controls. Sizes of US2 and US11 transcripts are indicated on the
right side of each blot. Cells infected with RV-KB6 were used as negative control.
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(US2pos) and RV-KB9 (US11pos) downregulated HLA-A2 on HFF in
the course of infection. Almost no signal above the background was
detectable anymore at late stages of infection. An identical course of
HLA-A2 expression was found when the cells were coinfected with
RV-KB13 and RV-KB9 (Fig. 5A). These results conﬁrmed that HLA-A2
was sensitive to either gpUS2 or gpUS11 attack. They further showed
that both evasins were highly effective in downregulating HLA-A2 in
HCMV infected cells.
The same experiments were carried out using an HLA-B7 speciﬁc
antibody (Fig. 5B). Infection of HFF with RV-KB9 resulted in
intermediate reduction of HLA-B7 in comparison to RV-BADwt
infection. Downregulation of HLA-B7 was also seen after retroviral
transduction of gpUS11 (Barel et al., 2006). In contrast to gpUS11,
gpUS2 failed to downregulate HLA-B7 after ectopic expression of the
evasin in transfected or transduced cells (Barel et al., 2003a, 2006;
Gewurz et al., 2001b; Llano et al., 2003). To evaluate, whether HLA-B7
was also resistant against gpUS2 in infected cells, HFF were infected
with RV-KB13 and tested by FACS analysis. Surprisingly, RV-KB13
infected HFF showed a pronounced reduction of HLA-B7 that was
exceeding the reduction seenwith RV-KB9 (Fig. 5B). The same level of
reduction was seen after coinfection with both viruses. Identical
results were obtained after RV-KB13 infection of two other HLA-B7
expressing HFF-lines (data not shown). Taken together these results
demonstrated that the sole expression of gpUS11 in HCMV infectedHFF has a strong downregulatory effect on HLA-A2 and amodest effect
on HLA-B7 surface expression. Infection with the gpUS2pos mutant
also leads to a marked downregulation of HLA-A2. Inconsistent with
gpUS2-HLA-B7 coexpression experiments, however, infection of HLA-
B7 positive HFF with the gpUS2pos mutant of HCMV led to a distinct
reduction of B7 surface expression over time. The latter results
underline the importance of studying the function of immunomodu-
latory HCMV proteins in the context of infection in order to deﬁne
their role in evasion.
Infected HFF stimulate IFNγ secretion by pp65- and IE1-speciﬁc CTL
despite gpUS2 or gpUS11 expression
Analysis of MHC class I surface expression levels by ﬂow cytometry
provides only limited information about the functionally relevant
impact of immune evasion on CTL recognition. Small numbers of MHC
class I peptide complexes on the cell surface, undetectable by the
sensitivity of the FACS analysis, may be sufﬁcient for CTL activation
and, ultimately, for killing of the target cell. We thus investigated the
role of gpUS2 and gpUS11 in functional antigen presentation by HCMV
infected cells using IFN-γ Elispot analyses. CTL clones derived from
HLA-A2 transgenic mice were used which were directed against
immunodominant HLA-A2 presented peptides from the tegument
protein pp65 and the regulatory IE1 protein of HCMV (Besold et al.,
2007). In contrast to human CTL lines, these clones can be cultured
indeﬁnitely, thus enabling the repetition of experiments under com-
parable conditions.
We ﬁrst tested the capacity of mutant virus infected HFF to present
a pp65 derived peptide. Infected cells were subjected to Elispot
analysis after various intervals p.i., using pp65NLV-CTL [speciﬁc for the
pp65 derived nonapeptide NLVPMVATV (Diamond et al., 1997);
Fig. 6A]. At 24 h p.i., cells infected with the gpUS2pos virus RV-KB13
or the gpUS11pos virus RV-KB9 showed a slightly reduced percentage
of spot numbers, as normalized to the numbers obtained with the
gpUS2–11neg mutant RV-KB6 (taken as 100%). This effect was
overcome at later stages of infection (72 h and 96 h p.i.). In contrast
to that, cells infected with the gpUS2–11pos strain RV-BADwt showed
the well-known kinetics of pp65 peptide presentation (Besold et al.,
2007), namely a marked impairment of presentation already at 24 h
and a gradual decrease at later stages of infection. This was inversely
correlated with the amount of pp65 protein, found in RV-BADwt
infected cells, as visualized by quantitative Odyssey® infrared
immunoblot. Infected cell lysates were probed with a pp65 speciﬁc
monoclonal antibody and protein amount was normalized to β-actin
(Fig. 6B).
To test, whether the effects of gpUS2 and gpUS11 were additive,
HFF were also coinfected with RV-KB13 and RV-KB9. Surprisingly,
there was an only slight reduction in spot numbers after coinfection,
compared to that observed after infection with either one of the
mutants (Fig. 6A). This indicates that gpUS2 and gpUS11 do not
functionally cooperate in exporting HC from the ER, thereby sup-
pressingMHC class I mediated peptide presentation at the cell surface.
Taken together, these experiments showed that the expression of
gpUS2 and gpUS11, alone or in combination, by HCMV infected cells
was insufﬁcient to prevent induction of IFN-γ secretion by pp65
speciﬁc CTL.
The experiments presented so far provided an apparent discre-
pancy. Expression of gpUS2 or gpUS11 in infected cells alone was
sufﬁcient to reduce HLA-A2 cell surface expression to basal levels,
comparable to what was seen with the gpUS2–11pos wt virus RV-
BADwt. In contrast, presentation of a peptide from pp65 by HLA-A2
was only slightly impaired at early times p.i. with US2pos or US11pos
expressing viruses and showed no impairment at later stages of
infection. Note that at late stages, HLA-A2 suppression, as measured
by FACS was maximal for all viruses tested (Fig. 5A). One explanation
for the dichotomy of HLA-A2 expression and pp65NLV presentation by
Fig. 4. Cytoﬂuorometric analysis of MHC class I surface expression of HFF, infected with the recombinant viral strains. Cells were infected with viral inocula that were normalized for
an uptake of 125 viral genomes per cell. At the indicated time points p.i., total MHC class I surface expression was measured using an HLA-ABC speciﬁc mAb for staining (clone W6/
32). Antibody binding was visualized with FITC-conjugated polyclonal anti-mouse antibodies and analyzed by ﬂowcytometry. Secondary antibody background staining was analyzed
for each sample. Coinfection was performed using viral inocula of each one of the two viral strains that were normalized for an uptake of 125 viral genomes per cell. (A) Histogram
blots of one representative experiment. Secondary antibody background staining is shown by dotted lines, staining of mock infected cells by solid lines and staining of infected cells
by shaded graphs. Dashed vertical lines indicate the median of mock infected graphs at each time point p.i.. (B) Means and standard deviations of 3 independent experiments as
shown in A. For each sample, the speciﬁc mean ﬂuorescence intensity (MFI) was calculated by subtracting the backgroundMFI (only secondary antibody) from theMFI obtained after
staining with both primary and secondary antibodies. For each time point p.i. the speciﬁc MFI of RV-KB6 (US2–11neg) infected cells was deﬁned as 100% MHC class I surface
expression (shown as dashed line in the graph).
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was limited in its power to predict functional antigen presentation in
general. Alternatively, it could be assumed that pp65 or the pp65NLV
peptide was exceptional in a way to allow presentation despite the
marked reduction of HLA-A2, seen by FACS. To test this, the MHC class
I presentation of another antigen, the IE1 protein was investigated.
Cells were infected with the different viruses and tested by Elispot forthe presentation of the IE1 derived peptide TMYGGISLL (IE1TMY;
(Gallez-Hawkins et al., 2003), using a speciﬁc CTL clone [IE1TMY-CTL;
(Besold et al., 2007); Fig. 6A]. Again, the numbers of spots were
calculated relative to the numbers obtained with cells, infected with
the US2–11neg virus RV-KB6. As opposed to the presentation of
pp65NLV, the presentation of the IE1 derived peptide was signiﬁcantly
impaired in cells that were infected with the gpUS2pos or the
Fig. 5. Cytoﬂuorometric analysis of HLA-A2 and -B7 surface expression of HFF, infectedwith the recombinant viral strains. HLA-A2- or HLA-B7-positive HFF were infectedwith anmoi
of 5 and, at the indicated time points p.i., incubated with HLA-A2 speciﬁc mAb (clone BB7.2) (A) or HLA-B7 speciﬁc mAb (clone BB7.1) (B) and PE-conjugated polyclonal anti-mouse
antibodies. Subsequently, mean ﬂuorescence intensities (MFI) were analyzed by ﬂow cytometry. Secondary antibody background staining was quantiﬁed for each sample. For
coinfection, each one of the viral strains was applied with anmoi of 5. Means and standard deviations of 3 independent experiments are shown. For each sample, the speciﬁc MFI was
calculated by subtracting the background MFI (only secondary antibody) from the MFI obtained after staining with both primary and secondary antibodies. For each time point p.i.
the speciﬁc MFI of RV-KB6 (US2–11neg) infected cells was deﬁned as 100% HLA-A2 (A) or -B7 (B) surface expression (shown as dashed line in graph B).
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RV-KB9 infected cells at 24 h p.i.. Some presentation became apparent,
however, at later times. Coinfection with both viruses com-
pletely abrogated any measurable presentation of IE1TMY. This was
comparable to the well-known complete suppression of IE1 presenta-
tion on cells that were infected with a US2–11 competent wt virus like
RV-BADwt that was used here (Besold et al., 2007; Gilbert et al., 1993;
Manley et al., 2004). Similar results were obtained using a second
HLA-A2 restricted CTL clone, directed against the IE1 derived peptide
VLEETSVML [IE1VLE; (Retiere et al., 2000); data not shown]. Suppres-
sion of IE1 presentation was in the face of signiﬁcant levels of the IE1
protein in infected cells, as exempliﬁed here using RV-BADwt infected
HFF (Fig. 6B). These results indicated that both gpUS2 and gpUS11
were individually sufﬁcient to suppress IE1 presentation at early times
after infection. However, suppression appeared to become leaky at
later stages, possibly correlating with the decrease in expression rates
for US2 and US11 (see Fig. 3).
Fusion of IE1TMY to pp65 restores its presentation by gpUS11pos
infected cells
CTL against pp65NLV are highly prevalent and can be found in high
frequencies in individuals expressing the HLA-A2 allomorph. This
peptide has consequently been labelled as being immunodominant
(Elkington et al., 2003; Wills et al., 1996). Speciﬁc features of pp65NLV,
like efﬁciency of its generation by the proteasome or afﬁnity to the
HLA-A2 molecule may explain its presentation despite gpUS2 or
gpUS11 expression in infected cells. Alternatively, special properties of
the carrier molecule pp65 may have been the reason for the limited
efﬁcacy, by which gpUS2 and gpUS11 could suppress pp65NLV pre-
sentation. To analyze this, we used a previously established recombi-
nant of HCMV (RV-VM3) which carries the IE1TMY peptide as integralpart of pp65 (Mersseman et al., 2008a; Fig. 7A). This virus, based on
the backbone of strain Ad169 derivative RV-HB5 (Borst et al., 1999)
expresses only US11, but none of the three other evasin genes. We
hypothesized that, if the characteristics of pp65 were important for
the limited efﬁcacy of gpUS11-mediated immune suppression, then
the pp65NLV presentation phenotype should be transferable to IE1TMY,
expressed as part of the pp65 protein in RV-VM3 infected cells.
Consequently, RV-VM3 infected cells (expressing the pp65-IE1TMY
fusion protein) were analyzed by Elispot, using IE1TMY-CTL and
pp65NLV-CTL as responder cells (Fig. 7B). Mutants RV-HB5 (Borst et
al., 1999), RV-Hd65 (Besold et al., 2007) and RV-ΔUS2–11(Falk et al.,
2002) were used for control (Fig. 7A). Cells infected with RV-HB5
showed no presentation of IE1TMY at 24 h p.i., as expected. Note that
concordant with the results obtained with RV-KB9 some IE1-
presentation became visible at later time points after infection (see
Fig. 6A). In contrast, however, the IE1TMY was already presented at
24 h p.i. by RV-VM3 infected cells, and this presentation increased
signiﬁcantly throughout later phases of infection. These data showed
that IE1TMY assumed the pp65NLV presentation phenotype in gpUS11
expressing infected cells. To investigate the levels of pp65-IE1TMY
fusion protein and to exclude IE1-overexpression in RV-VM3 infected
cells, a quantitative Odyssey® infrared immunoblot analysis was
carried out. Infected cell lysates were probed with a pp65 speciﬁc
monoclonal antibody. The amount of the fusion protein was normal-
ized to β-actin (Fig. 7C). As expected, the amount of pp65-IE1TMY
fusion protein increased substantially in the course of infection. This
was consistent with the kinetics of pp65 expression during infection
of HFF with an Ad169 derived strain, expressing the wt-pp65 (Fig. 6B,
left). In contrast, the level of the IE1 protein remained at about the
same level between 24–96 h p.i., excluding an enhanced IE1
expression in RV-VM3 infected cells as the cause for enhanced
IE1TMY presentation. These ﬁndings showed that pp65 is an
Fig. 6. (A) IFN-γ Elispot analysis of cells infected with the recombinant viral strains using pp65NLV- (left panel) or IE1TMY-CTL (right panel). HFF were either mock infected or infected
at an moi of 5 with the recombinant viral strains and were analyzed for their HLA-A2 restricted pp65NLV and IE1TMY presentation. For coinfection, each of the viral strains was applied
with an moi of 5. Means and standard deviations of 4 independent experiments are shown. For each time point p.i., the number of IFN-γ producing CTL that was obtained after
infection with the US2–11neg virus RV-KB6 was taken as maximal value and was deﬁned as 100%. (B) Quantitative Western blot analysis using the Licor Odyssey® infrared imaging
system. HFF were either mock infected or infected at an moi of 5 with wild type strain RV-BADwt. At the indicated time points p.i., cell lysates were separated by SDS-PAGE and, after
blotting, probed with mAb speciﬁc for pp65 (65-33) (left panel) and IE1 (p63-27) (right panel). A human actin speciﬁc polyclonal antiserumwas used for normalization. To visualize
primary antibody binding, infrared dye labelled secondary antibodies were used. Fluorescence intensities were measured using the Licor Odyssey® Software. To calculate relative
amounts of both pp65 and IE1 content within infected cells for each time point p.i., the ﬂuorescence intensity obtained after staining against each one of the two viral proteins was
divided by the ﬂuorescence intensity obtained after staining for actin.
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peptides contained in this protein are only moderately suppressed
by gpUS11.
Killing of RV-KB13 and RV-KB9 infected cells by human CTL
Expression of gpUS2 or gpUS11 by HCMV recombinants affected
recognition by pp65NLV-CTL and IE1TMY-CTL to different levels. The
biological relevance of the limited IE1TMY stimulation by late stage
infected cells remained unclear in particular. We thus decided to
perform a further experiment where we addressed the impact of
gpUS2 and gpUS11 by recombinant viruses on cytotoxicity of pp65
and IE speciﬁc human T cell lines, using 51Chromium release assays
(CRA). We used CTL lines obtained from HCMV antibody seropositive,
HLA-A2 positive donors to further provide evidence that the results
obtained with murine CTL clones were relevant to human CTL
recognition. These CTL lines were established as described previously
(Weekes et al., 1999;Wills et al., 1996), using autologous PBMC, pulsed
with either pp65NLV or the IE1VLE. T cell lines were tested for peptide
speciﬁc and HLA-A2 restricted cytotoxicity, using peptide pulsed
autologous and mismatched EBV transformed B cells (not shown).
These cytotoxic and HLA-A2 restricted T cell lines were used as
effector cells in CRA against autologous, donor derived dermal HF,
infected with RV-KB13 or RV-KB9 as target cells. Targets were infected
at an moi of 10 for either 24 h or 72 h and were then subjected to a
20 hour CRA (Fig. 8). Cells infected with the gpUS2pos RV-KB13 or the
gpUS11pos RV-KB9 were lysed at 72 h p.i., using pp65-speciﬁc human
CTL lines. Yet the percentage of speciﬁc lysis was less, compared to
that of cells infected with the gpUS2–11neg RV-KB6. In accordance,secretion of MIP1beta by the pp65-speciﬁc CTL into the culture
supernatant, as measured by ELISA, was also reduced when RV-KB13
and RV-KB9 infected HF were used for stimulation (data not shown).
These results indicate that, with respect to the CTL and the assay used
for analysis, the relative impact of gpUS2 and gpUS11 on pp65-derived
peptide presentation by MHC class I may vary.
As expected, cells infected with the US2–11neg RV-KB6 were
efﬁciently killed by the IE1VLE-CTL (Fig. 8). These CTL also killed HF
infected with either RV-KB13 or RV-KB9, though, as was the case for
pp65, to reduced levels, compared with RV-KB6. Killing was more
pronounced, when HF were infected for 72 h. This was consistent with
the results of the Elispot analyses, where only late stage infected cells
were able to stimulate IE1TMY-CTL (see Figs. 6 and 7). Surprisingly,
even HF infected for 72 h with the US2–11pos parental strain RV-
BADwt were killed to some extent by IE1VLE-CTL, indicating that
expression of all four immune evasins was insufﬁcient to completely
block recognition by IE1-speciﬁc CTL at late stages of infection. Taken
together these experiments showed that gpUS2 and gpUS11 affect
presentation of abundant viral proteins by MHC class I on HCMV
infected cells, but that the sole expression of these viral evasins is
insufﬁcient to completely block CTL recognition in the course of
infection of permissive HF.
Discussion
The functional relevance of the US2–11 gene locus for CTL
recognition during HCMV infection is well documented by studies
showing that CD8 T cells from infected individuals can be preferen-
tially stimulated ex vivo by cells that are infected with a US2–11neg
Fig. 7. Impact of gpUS11 on the presentation of IETMY, expressed as part of a pp65 fusion protein. (A) Schematic representation of viral strains, used for analysis. The location of the orfs
encoding UL83 (pp65), US2, US3, US6 and US11 are shown by dark grey boxes. Dashed lines between arrowheads indicate deleted genomic regions. The position of the IE1TMYpeptide
within the primary structure of the pp65 fusion protein is indicated by a light grey box. (B) IFN-γ Elispot analysis of cells infected with the recombinant viral strains using pp65NLV-
(left panel) or IE1TMY-CTL (right panel). HFF were infected at an moi of 5 with RV-HB5 or RV-VM3 and, at the indicated time points p.i., were analyzed for their HLA-A2 restricted
pp65NLV and IE1TMY presentation. Infections with the pp65 deletion mutant RV-Hd65 and the immune evasion deletion mutant RV-ΔUS2–11 were used for negative and positive
controls. Means and standard deviations of triplicate samples from one out of three independent experiments are shown. (C) QuantitativeWestern blot analysis using the Odyssey®
infrared immunoblot imaging system. HFF were either mock infected or infected at an moi of 5 with the RV-VM3 mutant strain. At the indicated time points p.i., cell lysates were
separated by SDS-PAGE and after blotting probed as described in Fig. 6B. Relative amounts of the viral proteins pp65 (left panel) and IE1 (right panel) within infected cells at each
time point p.i. were calculated as described in Fig. 6B. RV-HB5, HCMV mutant, with a deletion in the US2–6 genes, which expresses gpUS11, but not gpUS2, 3 and 6. RV-VM3, HCMV
mutant, based on RV-HB5with an additional insertion of the IE1TMYpeptide coding sequence in the UL83 gene, encoding pp65. RV-Hd65, HCMVmutant, with the coding sequence for
the UL83 gene deleted. RV-ΔUS2–11, HCMV mutant with the genomic region encoding all genes between US2 and US11 deleted.
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Fig. 8. Cytotoxicity assay using polyclonal pp65NLV (left panel) or IE1VLE (right panel) speciﬁc human CTL lines at an effector/target ratio of 100:1. Autologous human dermal
ﬁbroblasts (HF) were infected at an moi of 10 with the recombinant viral strains and at the indicated time points p.i. were used as targets in 20 h 51Chromium release assay (CRA).
Means and standard deviations of at least triplicate samples are shown.
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demonstrate that cells infected with a US2–11neg virus efﬁciently
presented both IE1 and pp65 derived peptides (Besold et al., 2007).
However, presentation of the same antigens was either completely
abrogated (for IE1) or severely impaired (for pp65), when US2–11
genes were present in cells infected with the parental strain. Current
opinion in the ﬁeld is that the genes for US2–11 are sequentially
expressed in the course of HCMV infection and that the proteins
interfere with MHC class I biogenesis in a sequential manner (Ahn et
al., 1996). However, it remained unclear, whether US2–11 cooperate in
suppressing MHC I biogenesis or whether they can act widely
independent in different phases of the HCMV replication cycle. One
recent study using gpUS2/3 coexpression demonstrated that both
proteins cooperate in suppressing MHC class I downregulation
(Noriega and Tortorella, 2009). To address, how these ﬁndings relate
to the role of US2–11 in their natural context of HCMV infection, it is
essential to investigate the single members of these proteins
individually and in various combinations in infected cells. Here we
present, to our knowledge, the ﬁrst study that focuses on the impact of
individual evasins, namely gpUS2 and gpUS11 on functionalMHC class
I presentation of HCMV antigens in the course of infection.
During their pioneering studies, Jones and coworkers generated
HCMVmutants that had a US2pos or a US11pos phenotype, but lacked
the three other immune evasins (Jones et al., 1995; Jones and Sun,
1997). These mutants, however, were also deleted in the US4–5 and
US7–10 open reading frames. Binding to MHC class I HC in the ER has
been documented for the two ER-resident proteins encoded by US8 or
US10 (Furman et al., 2002; Tirabassi and Ploegh, 2002) and at least the
US10 gene product was found to delay MHC class I trafﬁcking.
Although expression of either US8 or US10 did not appear tomodulate
MHC class I surface expression (Ahn et al., 1997; Jones et al., 1995), an
impact of these two proteins, or the other proteins encoded in this
region during infection could not be excluded. We thus chose to
establish a set of newmutants which had US4–5 and US7–10 retained.
The resulting viral mutants had to be thoroughly characterized,
both genotypically and phenotypically. In particular, we could conﬁrm
that the release of progeny virus was unimpaired when three (RV-
KB9, RV-KB13) or four (RV-KB6) of the evasins were absent. We
further showed that the kinetics of viral DNA replication in cells
infected with these mutants was widely unaltered. The latter issue
had not been approached before and appears to be interesting
considering the studies that reported inﬂuences of US3 on gene
expression (Colberg-Poley et al., 1992). Our results indicate that the
deletion of US3 has no severe impact on the ability of the virus to
replicate its genome.
Infection with gpUS2pos and gpUS11pos viruses led to down-
regulation of HLA-ABC on infected HFF, as detected by ﬂow cytometry.
This showed that both proteins independently impair MHC class Isurface expression on infected HF cells. The level of reduction was
similar between the two viruses, but was less signiﬁcant compared to
cells infected with a strain that expressed all four immune evasins.
This is in agreement with the model that gpUS2–11 work coopera-
tively to downregulate MHC class I. According to this, one of the four
evasion proteins would not sufﬁce to effect the same level of MHC
class I attenuation as compared to their concerted action. Recent data
from transient systems appear to support this model of cooperation
(Noriega and Tortorella, 2009). HLA-A2 was more pronouncedly
downregulated by cells infected with the gpUS2 and gpUS11
expressing viruses, compared to total HLA-ABC, showing kinetics
and levels comparable to the gpUS2–11 competent virus. It thus
appeared that gpUS2 and gpUS11 were each sufﬁcient to mediate full
downregulation of HLA-A2. As a matter of fact, both proteins have
been shown to be effective in attacking HLA-A2, whereas they have
been reported to be less effective against other HLA types (Barel et al.,
2006). Consequently, the differences seen between HLA-ABC down-
regulation (Fig. 4) and HLA-A2 downregulation (Fig. 5) can be
attributed to the different susceptibilities of the different HLA
molecules to US2 and US11 mediated attack.
Downregulation of HLA-B7 surface expression on cells infected
with US2pos and US11pos viruses was less intense, compared to that
of HLA-A2. HLA-B7 expression was moderately reduced in cells
infected with the US11pos virus. This is in accordance with results
from others, showing that retroviral transduction of US11 leads to a
roughly 50% reduction of HLA-B7 on transduced cells (Barel et al.,
2006). We found, however, an even more pronounced downregula-
tion of HLA-B7 on cells infected with the US2pos virus. This effect was
not dependent on the ﬁbroblast line used, as it could be conﬁrmed
using two additional HLA-B7 expressing lines (data not shown). The
latter results appear to contrast with reports showing that gpUS2,
expressed in transfected or retrovirally transduced cells failed to
interact with HLA-B7 in the ER and was insufﬁcient to downregulate
HLA-B7 on the cell surface (Barel et al., 2003b, 2006; Gewurz et al.,
2001b; Llano et al., 2003). The reasons for this discrepancy are not
known at the current stage. The virus used in our analysis lacked all
three other evasin genes, excluding inﬂuence by any one of the other
immunomodulatory proteins gpUS3, gpUS6 or gpUS11. It has been
shown that gpUS2 binds to HLA-A2 in a region between the peptide
binding site and the α3-domain (Gewurz et al., 2001a). This region is
not conserved in HLA-B7 and thus interaction was not observed using
native gel shift analysis (Gewurz et al., 2001b). However, weak
interactions may not be accessible by this kind of assay. Discrepant
results with regard to the susceptibility of certainMHC class I alleles to
gpUS2 attack have been ascribed to the different amounts of MHC
molecules expressed in different cell types (Lilley and Ploegh, 2005). It
is thus reasonable to assume that gpUS2 behaves differently when
analyzed in the context of infection as opposed to its isolated
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importance to study the role of the immune evasion proteins in the
context of infection in order to gain insight in their role in viral
pathogenesis.
Cells infected with gpUS2 or gpUS11 expressing viruses were
efﬁciently recognized by CTL speciﬁc for the HLA-A2 presented
peptide pp65NLV. This was an unexpected result, considering the
efﬁcient HLA-A2 downregulation at the same time p.i.. This indicates
that despite low level HLA-A2 expression, as measured by ﬂow
cytometry, CTL may still bind to infected cells and may be activated to
secrete cytokines and to kill their cognate target cells. Immunodomi-
nance of a given peptide could serve as an explanation for this. CTL
against pp65NLV are found in high frequencies in HCMV seropositive
individuals and this peptide is thus considered to be an immunodo-
minant HLA-A2 presented antigen of the virus (Gillespie et al., 2000;
Waller et al., 2007; Wills et al., 1996). In accordance with this, the
IE1TMY was only barely presented in RV-KB13 or RV-KB9 infected cells,
indicating that gpUS2 and gpUS11 were sufﬁcient to suppress
presentation of that particular subdominant peptide by HLA-A2.
Interestingly, however, IE1TMY assumed the immunodominant phe-
notype of pp65NLV when expressed in fusion with pp65 (see Fig. 7).
Consequently, the properties of the peptide alone may not be
sufﬁcient to explain the discrepancy between HLA-A2 surface
expression and detectability by CTL. The viral protein that carries
particular peptide epitopes may thus play a central role. Additional
experiments are warranted to address this issue. One important
message from this, however, is that measuring MHC class I surface
expression on infected cells by ﬂow cytometry does not necessarily
correlate with functionally relevant antigen presentation. Conse-
quently, for analyzing the role of immune evasion during HCMV
infection, it is mandatory to include functional approaches like
cytokine secretion or cytolysis assays.
Given the expression kinetics of US2 and US11, one would assume
that these two genes signiﬁcantly contribute to suppression of pp65
presentation by MHC class I. Indeed there was impairment both in
cytokine secretion and cytolysis at 24 h p.i. when the gpUS2pos RV-
KB13 or the gpUS11pos RV-KB9 was used for infection of HF. This
suppressive effect was still visible in cytolysis assays using human CTL
at 72 h p.i., but was abrogated in the Elispot analysis at that time point.
It is likely that different experimental conditions account for this
difference in suppression. In any way, the experimental setup
employed to test for cytolysis using human CTL may well reﬂect
certain conditions during natural infection of humans, when HCMV is
replicating to high levels in infected organ tissues and cytotoxic T
lymphocytes are attracted in larger numbers to the site of infection.
Consequently it seems that both gpUS2 and gpUS11 alone have some
effect on pp65 derived antigen presentation.
Cells infected with RV-KB13 or RV-KB9 did not stimulate IFNγ
secretion by IE1TMY-CTL at 24 h p.i. and induced only very limited
numbers of spots at later time points. This indicated that gpUS2 and
gpUS11 have a pronounced impact on the presentation of IE1 derived
peptides. Surprisingly, however, CTL lines against the IE1VLE peptide,
generated from human donors showed about 30% cytolysis of cells
infected with RV-KB13 or RV-KB9 at 72 h p.i.. As discussed above the
experimental setups used in both Elispot analysis and CRA cannot
directly be compared; however, both approaches seem to indicate
that, also for IE1, suppression of peptide presentation by gpUS2 and
gpUS11 may be leaky at later times of HCMV infection. In line with
this, the expression of both US2 and US11 RNA was barely detectable
in Northern blots late in infection (Fig. 3). It thus is conceivable that a
decrease of gpUS2 or gpUS11 (Ahn et al., 1996; Lilley and Ploegh,
2005) accounts for the recovery of pp65 and IE1 presentation in RV-
KB13 and RV-KB9 infected cells.
The data presented here only refer to infected HF. It is unclear,
what the impact of gpUS2 or gpUS11 would be on antigen
presentation by other cell types, like professional antigen presentingcells. However, the primary goal of this analysis was to investigate,
howMHC class I antigen presentationwas impaired by US2 or US11 on
highly permissive cell types, such as HF. It could be assumed, though
not formally proven that the results obtained here may serve as a
model for infected organ cells. Such cells are obviously major targets
of CD8 T cells during the effector phase of the immune response.
Consequently, the role of gpUS2 and gpUS11 for antigen presentation
on these cells is of major interest, not only for our understanding of
the functionality of these proteins; it may also aid to approaches to
develop immunotherapeutic regimens against HCMV infection and
disease.
In conclusion, we have shown here that gpUS2 and gpUS11 affect
MHC class I presentation of HCMV infected cells in an antigen-
dependent manner. The results suggest that immune evasion of MHC
class I antigen presentation during HCMV infection is a dynamic
process, which is governed by a delicate balance between the efﬁcacy
of the viral immunomodulatory proteins on the one hand and the
ability of the infected cell to generate sufﬁcient numbers of MHC class
I complexes for cell surface presentation on the other hand. The work
presented here provides a further step in our understanding of the




Primary human foreskin ﬁbroblasts (HFF) were grown in mini-
mal essential medium (MEM; PAA, Cölbe, Germany), supplemented
with 5–10% fetal calf serum (FCS; Biochrom, Berlin, Germany), 2 mM
L-glutamin, 50 mg/l gentamycin and 0.5 ng/ml basic ﬁbroblast
growth factor (bFGF; Invitrogen, Karlsruhe, Germany). Autologous
primary human ﬁbroblasts were established and maintained as
recently described (Waller et al., 2007).
CTL clones speciﬁc for the HLA-A0201 (A2) restricted HCMV
derived peptides pp65495–503 (pp65NLV-CTL; Diamond et al., 1997;
Wills et al., 1996) and IE1297–305 (IE1TMY-CTL; Gallez-Hawkins et al.,
2003) were generated by peptide immunization of HLA-A2/huCD8
double-transgenic mice (a kind gift from L. Sherman, The Scipps
Institute, La Jolla, CA, USA). Details of establishment and culturing of
these cells were recently described (Besold et al., 2007).
Human CD8+ Tcells were prepared from PBMC of HCMV antibody
seropositive, HLA-A2 positive donors. In order to remove CD4+Tcells,
CD19+ B cells, CD14+ monocytes and CD16+ NK cells, PBMC were
stained with anti-CD4-, anti-CD19-, anti-CD14- and anti-CD16-FITC
(Becton Dickinson, Oxford, UK) followed by anti-FITC conjugated
MACSmicrobeads (Miltenyi Biotech, Surrey, UK) and passed through a
MACS LS column (Miltenyi Biotech, Surrey, UK).
Polyclonal, peptide speciﬁc CTL lines were generated by stimulat-
ing MACS puriﬁed CD8+ T cells with irradiated autologous peptide-
pulsed PBMC in RPMI medium, supplemented with 10% FCS, 10%
human AB serum and 5 IU/ml recombinant human IL-2 (provided by
the MRC Centralized Facility for AIDS Reagents, NIBSC, UK) and cul-
tured for at least 14 days. CTL lines were maintained by splitting and
feeding under the same conditions as mentioned above every 5 days.
Viruses
The HCMV strain RV-BADwt was reconstituted using the bacterial
artiﬁcial chromosome (BAC) pAD/Cre [provided by Thomas Shenk;
(Yu et al., 2002)]. This BAC contains the complete genome of the
HCMV laboratory strain Ad169. In pAD/Cre, the BAC vector is inserted
between the viral genes US28 and US29. Next to the vector sequence,
an expression cassette for the Cre recombinase is contained. These
heterologous sequences are ﬂanked by LoxP sites. Transfection of
pAD/Cre derived clones into HFF leads to the site-speciﬁc excision of
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sequences from the reconstituted viruses (Yu et al., 2002).
The recombinant viral strain RV-VM3 was generated by mutagen-
esis of the parental strain RV-HB5 (Borst et al., 1999). This virus
expresses the IE1297–305 (IE1TMY) T-cell epitope fused to the pp65
protein (Mersseman et al., 2008a). In this virus, the BAC vector is
inserted into the US2–US6 region of HCMV strain Ad169, thereby
deleting these genes. For control purposes, the recombinant viruses
RV-Hd65 (Besold et al., 2007) and RV-ΔUS2–11 (Falk et al., 2002)
were employed.
To generate virus stocks, HFF were infected and incubated in a
humidiﬁed, 5% CO2 atmosphere at 37 °C for 5 to 8 days until the
cultures displayed a complete cytopathic effect (CPE). Supernatants
were cleared by centrifugation for 10 min at 3000 rpm and stored in
aliquots at −80 °C. Virus stock titration was either performed by
counting IE1 positive cells 48 h p.i., stained with a monoclonal
antibody (mAb) against IE1 [p63-27; (Andreoni et al., 1989)] or by
quantifying intracellular viral genomes 6 h p.i. by HCMV speciﬁc
TaqMan PCR. Multiplicity of infection (moi) was deﬁned as the
number of IE1 positivity inducing units per cell. To correlate the moi
with the number of intracellular viral genomes, HFF were infected
with different mois. Six hours p.i. intracellular viral genomes were
quantiﬁed by TaqMan PCR. Infection at an moi of 0.1 resulted in a
number of roughly 4 intracellular viral genomes, infection at anmoi of
5 in a number of roughly 125 intracellular viral genomes. For growth
kinetics via TaqMan PCR, HFF were infected with viral inocula that
were normalized for an equivalent uptake of 4 viral genomes per cell.
For Northern blot analysis and for cytoﬂuorometric analysis of MHC
class I surface expression, HFF were infected with viral inocula
normalized for an equivalent uptake of 125 viral genomes per cell.
Cytoﬂuorometric analyses of HLA-A2 and HLA-B7 surface expression,
gamma interferon (IFN-γ) Elispot assays and Western blot analyses
were performed using HFF infected at an moi of 5. For 51Chromium
release assays human ﬁbroblasts (HF) were infected at an moi of 10.
BAC mutagenesis
Viral mutants were generated by BAC mutagenesis of the HCMV
BAC pAD/Cre (Yu et al., 2002) using Red recombination in E. coli strain
EL250 as described by Lee et al. (2001). For generation of BAC pKB6,
the orfs US2, US3, US6 and US11 were sequentially deleted. In a ﬁrst
step (step 1), orf US2 was deleted by inserting a kanamycin resistance
(KanR) gene. The KanR gene, ﬂanked by FRT sites, was ampliﬁed from a
derivative of vector pCP15 (Cherepanov and Wackernagel, 1995). In
addition to the priming sequence for the KanR FRT cassette ampliﬁca-
tion, the oligonucleotides contained, at their very 5′-ends, about 50 bp
of homology to the nucleotide sequences directly adjacent to US2.
The complete sequences of the primers were as follows: (primer KB1:
5′-ATGGGTACTCGTGGCTAGATTTATTGAAATAAACCGCGATCCCG-
GGCGTCTCGAGAAACGCAGCTTC-3′, and primer KB2: 5′-CTCTGGGA-
TATAAATTGGGAAAGAGCGTACAGTCCACACGCTGTTTCACCGG-
TACCCGGGGATCTTG-3′). After homologous recombination of the PCR
product into the viral DNA, individual colonies were selected by
addition of kanamycin. The KanR genewas then removed from the BAC
of individual clones by site-speciﬁc Flp recombination at ﬂanking FRT
sites. For this, Flp expressionwas induced in E. coli EL250 by arabinose
as originally described by Lee et al. (2001). The same strategy was
then used in the second step (step 2) to remove US11. For this, primers
with about 50 bp homology to the nucleotide sequences directly
adjacent to US11 were used (primer KB7: 5′-GGTGAGTCGTTTCCGAGC-
GACTCGAGATGCACTCCGCTTCAGTCTATATAGGTACCCGGGGATCTTG-3′,
and primer KB8: 5′-TTACAGCTTTTGAGTCTAGACAGGGTAACAGCCTTC-
CCTTGTAAGACAGATCGAGAAACGCAGCTTC-3′). Again, the KanR gene
was removed by Flp recombination. For deletion of orf US3, in the
third step (step 3), the KanR gene was used again, this time, however
lacking ﬂanking FRT sites. This strategy was chosen to avoid insertionof another FRT site into the HCMV genome. Therefore, one copy of the
KanR gene is contained in the ﬁnal BAC pKB6. The primers used for
ampliﬁcation were as follows: (primer KB3: 5′-GTACCTTGCAGCCCA-
GGTAGGTTTCAGGTACCAGCTGGTTCGTACCTGGGAATAGGAACTTCAAG-
ATCCCCC-3′, and primer KB4: 5′-GCAGCCAGACCGGAGCGGTGAGCGG-
AGCCGAGCAGCGGACCTTCGGAGCCCAGAGCGCTTTTGAAGCTGGG-3′).
Finally, for deletion of orf US6, in the fourth step (step 4), insertion
of an ampicillin resistance gene (AmpR) was used, which was also
ampliﬁed from the derivative vector of pCP15 (primer KB5: 5′- GAGA-
ATGCCGTGTTGAAGGAACGCGCTTTTATTGAGACGATAAAACAGCAGCG-
GAACCCCTATTTGTT-3′, and primer KB6: 5′- GAACATATATAATCGCCGT-
TTCGTAAGCACGTCGATATCACTCCTTCACTCTTGGTCTGACAGTTACC-3′).
To generate pKB13, the orfs US11, US3 and US6 were successively
deleted, using steps 2, 3 and 4, as described above. To obtain pKB9,
the orfs US2, US3 and US6 were successively deleted, using steps 1, 3
and 4 as described above. Reconstitution of BAC vector free wild type
RV-BADwt and recombinant viruses RV-KB13, RV-KB9 and RV-KB6
was carried out as described by Yu et al. (2002). Successful BAC vector
excision was controlled by PCR. For this, template viral DNA was
isolated from supernatants of infected cells using the high pure viral
nucleic acid kit according to the instructions of the manufacturer
(Roche Diagnostics, Mannheim, Germany).
DNA, RNA and protein analyses
For restriction enzyme analysis of the recombinant BACs, DNAwas
isolated from 200 ml of overnight bacterial cultures using the
Nucleobond AX 500 kit (Macherey-Nagel, Düren, Germany) according
to the manufacturer's instructions. The DNAwas digested with BamHI
for 6 h and separated on a 0.6% agarose gel at 60 V for 48 h. For
Southern blot analyses, the DNA was transferred onto nylon mem-
branes (Roche Diagnostics GmbH, Mannheim, Germany) and probed
with DIG-11-dUTP labelled DNA probes speciﬁc for US2, US3, US6 and
US11, respectively that were generated using the PCR DIG probe
synthesis kit according to the instructions of the manufacturer (Roche
Diagnostics). For generation of the probes, HCMV BAC pAD/Cre was
used as template. Primers that hybridized to the orf US2 (KB28:
5′-ACCGCATCCACATCATAGAC-3′, and KB29: 5′-CCCGATGGAATCACT-
AAAGC-3′), the orf US3 (KB30: 5′-TAAATCGCAGACGGGCGCTCAC-3′,
and KB31: 5′-GCCGTCTTGTTCCTGAGACTCG-3′), the orf US6 (KB32:
5′-CAGGAGCCACAACGTCGAATC-3′, and KB33: 5′-CTCTGTCTCCGCGA-
CAACAAG-3′) and the orf US11 (KB34: 5′-TGTCGGTGCAGCCAACCT-
TTC-3′, and KB35: 5′-ACCGCCTCTGTCCGATGTTTC-3′) were used for
ampliﬁcation. Probes were between 550 and 650 bp, and thus covered
large parts of the respective orfs.
For RNA preparation, cells were infected with viral inocula that
were normalized for an uptake of 125 viral genomes per cell. The RNA
was isolated using the RNeasy mini kit according to the manufac-
turer's instructions (Qiagen, Hilden, Germany). For Northern blot
analyses, 8 μg total cellular RNA per lane was electrophoretically
separated at 120 V for 5 h, using a 1% agarose gel, supplemented with
0.6% formaldehyde. RNA was transferred to nylon membranes (Roche
Diagnostics) and probed with the same DIG-11-dUTP labelled DNA
probes, speciﬁc for US2 and US11 that were also used for Southern
blot. Southern and Northern blot analyses were performed according
to the Roche DIG application manual for ﬁlter hybridization.
For quantitative Western blot analyses, infected or mock-infected
cell lysates, obtained from 105 cells for each lane, were electro-
phoretically separated using 10% polyacrylamide gels containing
10% sodium dodecyl sulfate (SDS) and transferred to PVDF mem-
branes (Immobilon-FL transfer membranes, Millipore, Schwalbach,
Germany). SDS polyacrylamide gel electrophoresis and Western
blotting were carried out as previously described (Schmolke et al.,
1995). After blotting, membranes were blocked for 1 h using 0.2% I-
Block (Applied Biosystems, distributed byApplera DeutschlandGmbH,
Darmstadt, Germany) in phosphate buffered saline (PBS). Primary
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Tween. Filters were incubated at room temperature overnight. Anti-
bodies directed against pp65 (mAb 65-33) and IE1 [mAb p63-27;
(Plachter et al., 1993)], both kindly provided by W. Britt, University of
Alabama, Birmingham, AL, USA) were diluted 1:500, rabbit polyclonal
antibody directed against actin (directed to amino acids 180 to 375 of
human actin; Santa Cruz Biotechnology, Heidelberg, Germany) was
diluted 1:200. After 3 washing steps in PBS, supplemented with 0.2%
Tween, primary antibody binding was detected using infrared labelled
secondary antibodies [IRDye 800 conjugated goat anti-mouse IgG
(H+L); Rockland, Gilbertsville, PA, USA; distributed by Biotrend, Köln,
Germany; Alexa Fluor 680 conjugated goat anti-rabbit IgG (H+L);
Invitrogen, Karlsruhe, Germany]. Membranes were incubated in the
dark for 1 h with secondary antibodies, diluted 1:10,000 in PBS
supplemented with 0.1% Tween and 0.01% SDS. Using dual ﬂuores-
cence, the detection of pp65 or IE1 on the one hand and cellular actin
on the other hand could be performed on the same ﬁlter. Antibody
binding was visualized using the Odyssey® infrared scanner (Licor
Biosciences). Fluorescence intensities were quantiﬁed using the Licor
Odyssey® Software. To calculate relative amounts of both pp65 and IE1
contentswithin infected cells, theﬂuorescence intensity obtained after
staining against each one of the two viral proteins was divided by the
ﬂuorescence intensity obtained after actin staining.
Growth kinetics
For single step growth analyses, HFF were infected at an moi of 5
with the different viral strains. Aliquots of cell culture supernatants
were harvested daily until complete cell lysis. IE1 forming units
within the supernatants were quantiﬁed by counting IE1 positive
cells 48 h p.i., stained with a monoclonal antibody (mAb) against IE1
[p63-27; (Andreoni et al., 1989)].
To quantify viral genomes accumulating within infected cells or
released into the supernatant during infection, a quantitative real-
time PCR using the TaqMan technology was performed. HFF were
infected with viral inocula that were normalized for an uptake of 4
viral genomes per cell. At each of the following 5 (intracellular
genomes) or 7 days (genomes released into the supernatant), viral
genomes were isolated from 105 infected cells or from a 200 μl aliquot
of the supernatant using the high pure viral nucleic acid kit (Roche
Diagnostics) according to the manufacturer's recommendations.
TaqMan PCR was performed in 50 μl reaction mixtures, containing
5 μl of either the viral DNA sample or standard DNA solution.
Additional components were 2 units HotStarTaq DNA polymerase
(Qiagen), 15 pmol of each primer and 5 pmol probe directed against
the HCMV gene UL54, which was labelled with 6-carboxy-ﬂuorescein
reporter dye and 6-carboxy-tetramethyl-rhodamine quencher dye.
The DNA standard for quantiﬁcation was prepared by serial dilutions
of 106 to 10 copies of cosmid pCM1049 (Fleckenstein et al., 1982). For
thermal cycling, two initial steps of 2 min at 50 °C and 15 min at 95 °C
were followed by 45 ampliﬁcation cycles consisting of 15 s at 94 °C and
1 min at 60 °C. Real-time PCR was performed using an ABI Prism 7700
sequence detector (PE Applied Biosystems, Weiterstadt, Germany).
For each DNA sample, PCR analysis was carried out in triplicates.
Flow cytometry
A ﬂuorescence-activated cell sorter (FACSort, Becton Dickinson,
San Jose, CA, USA) was used to analyze surface expression of MHC
class I, HLA-A2 and HLA-B7 on HCMV infected HFF cells. 5×105 HFF
were infected either at an moi of 5 or with viral inocula that were
normalized for an uptake of 125 viral genomes per cell. In coinfection
experiments, an moi of 5 or an infectious dose of 125 viral genomes
was applied for each virus to ensure that expression levels of gpUS2
and gpUS11 were comparable to the levels obtained after infection
with each individual mutant alone. Samples from 24, 48, 72 and 96 hp.i. were collected andwashed in FACS buffer (PBS supplementedwith
0.4% BSA, 10 mM EDTA and 20 mM HEPES). One half of the cells was
stained using the respective primary antibody while the rest was
mock stained with FACS buffer to detect secondary antibody back-
ground staining. Staining was performed for 30 min on ice in a ﬁnal
volume of 10–15 μl. For primary antibody staining, the HLA-ABC
speciﬁc mAb clone W6/32 (Dako, Hamburg, Germany), the HLA-A2
speciﬁc mAb clone BB7.2 (BD Biosciences, Heidelberg, Germany) and
the HLA-B7 speciﬁc mAb clone BB7.1 (AbD Serotec, Düsseldorf,
Germany) were used in dilutions of 1:15 (anti-HLA-ABC), 1:10 (anti-
HLA-A2) and 1:50 (anti-HLA-B7). After a washing step in FACS buffer,
secondary antibody incubationwas performed using a 1:15 dilution of
FITC-conjugated polyclonal rabbit anti-mouse immunoglobulines (Ig)
(Dako) or a 1:2 dilution of PE-conjugated goat F(ab′) anti-mouse IgG
(R&D Systems, Wiesbaden-Nordenstadt, Germany). After an addi-
tional washing step, cells were resuspended in FACS buffer and sub-
sequently subjected to cytoﬂuorometric analysis.
Gamma interferon (IFN-γ) Elispot assay
Elispot assays were performed according to published procedures
(Frankenberg et al., 2002; Miyahira et al., 1995). As stimulator cells,
either mock or HCMV infected HFF were used. Infections were carried
out at an moi of 5. For coinfection experiments, an moi of 5 was used
for each virus. Pp65NLV- and IE1TMY-CTL clones served as responder
cells (Besold et al., 2007). For each sample, 5×104 to 1×105 antigen
presenting cells were probed with 200 responder cells. Triplicate
samples were analyzed. Counting of spots was carried out using an
SZX-12 microscope (Olympus, Hamburg, Germany).
Cytotoxicity assay
Peptide speciﬁc CTL lines were assayed for cytotoxicity against
radiolabelled target cells in 20 h 51Chromium release assays as pre-
viously described (Wills et al., 1996). Autologous ﬁbroblasts were
infected at an moi of 10 and were used 24 and 72 h p.i. as target cells
for peptide speciﬁc CTL lines. Cytotoxicity assays were performed at an
effector/target ratio of 100:1. For control, autologous ﬁbroblasts and
EBV transformed B cell lines pulsed with 40 μg/ml peptide were also
used as target cells.
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